Opko Health Inc - Asset Resilience Ratio
Opko Health Inc (OPK) has an Asset Resilience Ratio of 0.49% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2020)
This chart shows how Opko Health Inc's Asset Resilience Ratio has changed over time. Check Opko Health Inc (OPK) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Opko Health Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Opko Health Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.75 Million | 0.49% |
| Total Liquid Assets | $11.75 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Opko Health Inc maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Opko Health Inc Industry Peers by Asset Resilience Ratio
Compare Opko Health Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Thyrocare Technologies Limited
NSE:THYROCARE |
Diagnostics & Research | 20.28% |
|
Shanghai Runda Med Tech Co
SHG:603108 |
Diagnostics & Research | 0.42% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
BioPorto
CO:BIOPOR |
Diagnostics & Research | 55.77% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
Annual Asset Resilience Ratio for Opko Health Inc (2001–2020)
The table below shows the annual Asset Resilience Ratio data for Opko Health Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.00% | $-11.00K | $2.47 Billion | 0.00pp |
| 2019-12-31 | 0.00% | $48.00K | $2.31 Billion | +0.00pp |
| 2018-12-31 | 0.00% | $27.00K | $2.45 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $2.59 Billion | -- |
| 2016-12-31 | 0.00% | $-33.00K | $2.77 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $2.80 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $1.27 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $1.39 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $289.83 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $229.49 Million | -- |
| 2004-12-31 | 11.16% | $1.12 Million | $10.07 Million | +5.87pp |
| 2003-12-31 | 5.29% | $600.00K | $11.34 Million | -51.83pp |
| 2002-12-31 | 57.12% | $10.00 Million | $17.52 Million | +18.75pp |
| 2001-12-31 | 38.37% | $10.60 Million | $27.62 Million | -- |
About Opko Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigen… Read more